studies

More documents

Recommendations

Info

1370A CATEGORY INDEX HEPATOLOGY, October, 2015 Efficacy of Grazoprevir (GZR 715 High Efficacy of Grazoprevir 251 High Efficacy of Grazoprevir 210 High Efficacy of the Combina 701 High SVR4 Rates Achieved Wit 250 High SVR4 Rates Achieved Wit 248 Improvement in liver disease 706 Integrated Safety Analysis o 726 No Clinically Meaningful Pha 725 No Pharmacokinetic Interacti 731 No Pharmacokinetic Interacti 730 Ombitasvir/Paritaprevir/r an 722 Predictors of Response to Gr 700 Resistance Analysis of Treat 713 SVR12 results from the Phase 39 Safety and Tolerability of G 712 Safety and efficacy of dacla 37 Short-duration therapy with 702 Sofosbuvir/GS-5816 Fixed Dos 249 The Combination of Grazoprev 703 A Pilot Evaluation of Twice 724 C-EDGE CO-STAR: Efficacy of 40 C-EDGE Co-Infection: Impact 729 C-EDGE TN: Impact Of 12-Week 717 Comparative Efficacy and Tol 711 Efficacy, Safety And Pharmac 707 High Rates of SVR in Treatme 247 Pharmacokinetics of Coadmini 719 Pharmacokinetics of Narlapre 721 Prevention of allograft HCV 704 Projected Long-Term Impact o 727 Sofosbuvir/GS-5816+GS-9857 f 38 FO5. Therapeutics: Approved Agents (THE SOFGER TRIAL) Sofosbuvi 1078 IFNL4 ss469415590 Polymorphi 1149 Adherence to All-Oral HCV Tr 1063 Asian Patients with Chronic 1080 Asian Patients with Genotype 1105 Association of polymorphisms 1055 Clinical Management of Ribav 1067 Co-morbidities and co-medica 1140 Combination of IFNL4 polymor 1153 Combination therapy with dac 1125 Comparison of 8 vs. 12 weeks 1036 Demographic Predictors of Di 1048 Early and persistent increas 1070 Early dose adjustment of RBV 1162 Effect of Chronic Kidney Dis 1088 Effectiveness of Ledipasvir/ 93 Effectiveness of Treatment o 1155 Efficacy and Adverse Event P 1119 Efficacy and Safety of Simep 1118 Efficacy and Safety of Sofos 1165 Efficacy and safety of IFN-f 1092 Efficacy of Ledipasvir plus 1146 Evaluation of the efficacy a 1191 Global prevalence of pre-exi 1044 Hepatic Decompensation and S 1185 Hepatitis C treatment with S 1102 Hepatitis C virus NS5A L31V 1082 Hepatocellular carcinoma dev 1056 High efficacy of a 12-week s 1179 High efficacy of ledipasvir/ 1049 Highly Successful Retreatmen 92 IFN-λ inhibits miR-122 tran 1096 IFN-free DAA regimens improv 1204 Impact of baseline albumin l 1040 Lower 25-OH Vitamin D Levels 1109 NS3 Q80K Polymorphism in Vir 1127 Ombitasvir/Paritaprevir/r an 1084 Outcomes of ribavirin free r 1174 Patient Decision-Making: The 1114 Patient Expectations of the 1152 Patient Reasons for Initiati 1139 Pharmacokinetic Analyses of 1133 Pre-Existing Co-Morbidities 1200 Prediction for poor virologi 1062 Prevalence of Pre-Treatment 91 Quality-Adjusted Cost of Car 1079 Quantifying and Predicting E 1145 Real Life Treatment Outcomes 1154 Real-world effectiveness and 1176 Real-world effectiveness of 1205 Resistance Analyses of Phase 1168 Retreatment with sofosbuvir 1123 Ribavirin levels at treatmen 1098 Safety and Efficacy of All-O 1126 Safety and Efficacy of Sofos 1057 Safety and Efficacy of Treat 1128 Simeprevir plus sofosbuvir f 1072 Simeprevir, pegylated-interf 1192 Sofosbuvir, Ledipasvir in IB 1075 Sofosbuvir (SOF) and Ledipas 1035 Sofosbuvir + Ledispasvir Com 1101 Sofosbuvir Plus Ribavirin Wi 1094 Sofosbuvir and Ledipasvir/So 1120 Sofosbuvir and Ribavirin for 1083 Sofosbuvir and ledipasvir fo 1081 Sofosbuvir in combination wi 1091 Sofosbuvir plus Ribavirin in 1076 Sofosbuvir-based antiviral t 1158 Sofosbuvir-based treatments 1156 Sofosbuvir-based treatments 1060 Sustained Virologic Response 1043 The TOSCAR Study: Sofosbuvir 1077 The effect of interferon-fre 1047 Treatment Outcomes With 8, 1 94 Treatment of Chronic HCV Gen 1170 Treatment of Chronic Hepatit 1122 Treatment of Hepatitis C Gen 1163 Treatment of Hepatitis C Vir 1186 Virological and Clinical Res 1190 What does Fibroscan® measur 1137 Is ribavirin actuall 1187 ITPA polymorphisms are predi 1193 Interferon Signaling and the 1132 A Meta-Analysis of the Assoc 1129 A comparison of direct seque 1061 Adherence and Discontinuatio 1050 An Actuarial View of the Agi 1069 Approved All-oral Sofosbuvir 1034 Assessment of serum hepatiti 1207 Association between severe r 1138 Awareness Of Hepatitis C Sta 1042 Better Work Productivity and 1198 Cardiac arrhythmia in patien 1194 Clinical Significance of Blo 1203 Clinical- and Economic-perfo 1095 Combination therapies with d 1150 Concomitant use of chemother 1160 Cost-effectiveness of ombita 1143 Daclatasvir plus sofosbuvir 1058 Detecting Drug-Induced Liver 96 Determination of on-treatmen 1103 Differences in NK phenotype 1117 Early response and efficacy 1167 Effect of Different Immunosu 1045 Effect of Proton pump inhibi 1199 Effect of Renal Function on 1066 Effectiveness of 12 or 24 we 1108 Effectiveness of 8 or 12 wee 1046 Efficacy and safety of dacla 1116 Efficacy and safety of ombit 1107 Efficacy of Daclatasvir/Asun 1097 Efficacy of Sofosbuvir and S 1206 Efficacy of combination ther 1157 Efficacy, Change in MELD Sco 1106 Evaluation of an Integrated 1136 Frequency of Renal Impairmen 1099 Frequent Emergences of Rare 1064 HCV genotype 3: Meta-analysi 1134 Health Outcomes and Cost Eff 1089 Health resource usage in per 1173 HepCure: An Innovative web-b 1151 Hepatitis C Cure Could Avoid 1054 Hepatitis C Cure Results in 1202 Hepatitis C and HCC Outcomes 1124 High prevalence of co-morbid 1052 High ribavirin dose and exte 1201 Hope and Hopelessness in HCV 1177 IFN and/or RBV-Free Therapy 1189 Improving liver function and 95 Lifetime risks of liver morb 1087 Lifetime risks of liver morb 1144 Limited Effectiveness of Sof 1164 Long-Term Efficacy of Ombita 1086 Multicenter Experience using 1038 Ombitasvir/Paritaprevir/r an 1161 On-treatment HCV RNA Decline 1130 Patterns of Care Since the A 1141 Potential for drug-drug inte 1093 Predictors of Treatment Adhe 1175 Preliminary Experience Of Di 1148 Preliminary Safety and Effic 1065 Prevalence of drug-drug inte 1131 Prospective Study for The Ef 1100 RUBY-I: Ombitasvir/Paritapre 1039 Rapid drop in serum glucose 1180 Rapid virological response a 1110 Real Life Experience of Dire 1104 Real Life Experience with So 1121 Real World Effectiveness Of 1188 Real-Word Effectiveness of L 1053 Resistance-associated varian 1115 Resistant-associated variant 1197 Ribavirin Levels and Transpo 1196 Safety And Efficacy Of The C 1073 Safety And Efficacy Of Two I 1147 Similar Tolerability and Eff 1182 Sofosbuvir Combination Thera 1184 Sofosbuvir and Ledipasvir fo 1111 Sofosbuvir and Ledipasvir in 1037 Sofosbuvir and Ledipasvir ve 1074 Sofosbuvir in the Treatment 1090 Sofosbuvir is well tolerated 1178 Sustained Virologic Response 1169 Telaprevir in the Treatment 1112 The Significance of Immunoal 1059 The Time and Cost Investment 1172 The healthcare cost burden o 1068 The number needed to treat w 1166 Therapeutic effect of dual o 1159 Transient renal dysfunction 1113 Treatment Outcomes of Vetera 1142 Treatment of recurrent Hepat 1181 Turquoise-III: 12-Week Ribav 1051 Twelve Weeks of Sofosbuvir p 1041 Utility of acoustic radiatio 1195
HEPATOLOGY, VOLUME 62, NUMBER 1 (SUPPL) CATEGORY INDEX 1371A Utilization and Effectivenes 1135 Utilizing claims data to und 1085 Virological efficacy of new 1171 “Real-life”-Experience w 1183 Hepatobiliary Neoplasia GO1. Experimental Hepatocarcinogenesis Alpha fetoprotein harbors a 1977 CD26 (DPP-4) as a molecular 1937 Cholangiocarcinoma cells int 1993 Co-activation of AKT and c-M 1934 Colorectal liver metastasis 1969 Correlation between Incidenc 1991 Deregulated Interplay Betwee 1952 Development of HCC is depend 1971 EVI1 is a target for gene am 1980 Efficacy and mechanism of de 1941 Expression of Transforming G 1962 FGF15 and FGF19 Induce Dispa 1986 Fibrotic liver microenvironm 1970 Glypican 3 (GPC3)-CD81 axis 1979 Glypican 3 contributes to HC 1967 HCV Core Gene Mutations with 229 Hepatic Ruvbl1 is key regula 1963 Hepatocyte-derived osteopont 1940 Hyperinsulinemia, not hyperg 1981 Liver Selective Acetyl-CoA C 1938 Macrophage colony-stimulatin 1956 Mevalonate pathway targets F 1974 MicroRNA profiling of human 1992 MicroRNA-207 controls Prp19 1964 Notch-1 Up-regulated Rat Ova 1951 Oxysterols Promote Malignant 1994 P300 promotes TGF-β stimula 1947 Platelet-Derived Growth Fact 1950 Promoted malignant tumor phe 1968 Promotion of Hepatocarcinoge 1957 Steatosis Induces Wnt/Β-Cat 1945 Survival of hepatocellular c 1960 The Long Noncoding RNA SNHG6 1939 The analyses of oxidative DN 1984 The relationship between hep 1944 Truncated Hepatitis B virus 1946 Voluntary exercise opposes a 230 Baicalein targets liver tumo 1936 Branched chain amino acids p 1982 Chronic alcohol accelerates 1958 Classification of tumors bas 1935 Continuous hepatocyte apopto 1985 Critical role of Hippo casca 1948 Cytotoxic synergy between so 1972 DDB2 loss protects mice from 1988 DNA methylome and cancer-spe 1983 Differential Antitumor Effec 1966 Hepatocyte-specific overexpr 1949 Inactivation of Aldose Reduc 1961 Inflammation contributes to 1989 Inhibition of autophagy reve 1943 Lymphotoxin–β regulated b 1987 Osteopontin is a novel surro 1976 Osteopontin-c isoform promot 1978 PPPDE1 is a deubiquitinase t 1973 PTEN Expression Affects the 1942 Regorafenib inhibits ERK sig 1953 Regulator of G-protein signa 1990 Retrospective cohort study f 1975 Significance of connective t 231 Sitagliptin, a Dipeptidyl Pe 233 Somatic Mutational Analysis 1965 The Dead Box Protein P68 Can 1954 Two-step forward genetic scr 234 Variations of the host genom 1959 p62 is a Key Regulator for I 232 GO2. Diagnostics and Liver Imaging A mass spectrometry based se 1900 ARID1A mutations may represe 1901 Circulating tumor DNA analys 1895 DNA Methylation Markers for 169 Diagnostic Performance of Co 1897 Efficacy of Delta-AFP in Pre 1899 Evaluation of PIVKA-II effic 1898 LI-RADS hepatocellular carci 1906 Transforming acidic coiled-c 1902 Transjugular Intrahepatic Po 172 A Model to Estimate Survival 1907 A Retrospective Cohort Study 1904 Correlation of MR and pathol 1896 High 18F-FDG uptake on preop 1893 Reduced sensitivity of ultra 1894 The role of AFP in screening 1903 GO3. Clinical: Hepatocellular Carcinoma and Cholangiocarcinoma A Single Center Experience w 428 A Study for the Risk Factors 131 A potential biomarker, Brf1 460 A stromal liver gene signatu 364 Activation of Stemness Genes 366 Albi score predicts survival 489 Analyses of progressive dise 482 Aspirin Use is Associated wi 397 Cholangiocarcinoma, a signif 416 Circulating Osteopontin and 170 Clinical Features and Treatm 486 Clinical significance of mic 426 Combining transarterial chem 391 Comparative Effectiveness of 357 Comparison of balloon-occlud 411 Diabetes, HBV infection and 132 Differences between radiolog 413 Differences in Presentation 387 Doxorubicin Resistance in He 352 Efficacy of Continuous Nucle 439 Ethnicity impacts aggressive 362 Etiology-Specific Effect of 415 Hepatic function and tumour 444 Hepatocellular Carcinoma Sur 442 Heterogeneity of advanced he 473 High gamma-glutamyl transfer 389 Hong Kong Liver Cancer stagi 409 Impact of Hepatic p62 Overex 456 In patients with HCC and mac 421 In patients with hepatocellu 449 Influence of hepatitis B vir 405 Intrahepatic Cholangiocarcin 372 Lamivudine vs. Entecavir for 422 Liver microRNA hsa-miR-125a- 431 Liver-directed (LD) Therapy 481 MESIAH score is an effective 470 Meta-Analysis: Proportions o 367 MicroRNA expression in hepat 429 Model to predict recurrence 400 Multi-platform analysis of T 129 Non-Cirrhotic Hepatocellular 488 Optimal age to start surveil 350 Oral nucleos(t)ide analogues 349 Outcomes following Radiofreq 174 Outcomes of patients with re 491 Patients with alcohol compar 373 Preclinical characterization 394 Predicting Tumor Death – T 369 Prediction of Hepatocellular 381 Prediction of liver decompen 450 Prognostic Score predicting 467 Prognostic assessment of pat 355 Prognostic significance of i 376 Progranulin Autoantibodies a 463 Reappraisal of portal vein t 479 Retreatment with TACE: Trans 447 Risk Differences of Hepatoce 359 Risk assessment of hepatocel 346 Risk factors of complication 171 Screening Practices for Hepa 401 Serological markers of extra 441 Short-term preoperative trea 417 Significant Suppression of L 410 Simple serological tests and 475 Staging Hepatocellular Carci 425 Stereotactic Body Radiothera 471 Surveillance at six month in 374 Survival After Intra-Arteria 344 Survival analysis of second 472 TBI 302: A first-in-class th 424 Targeting the TGF-β Pathway 130 The Doylestown algorithm – 371 The autophagy marker LC3 is 398 The effect of additional tra 464 The life time frequency and 382 The role of cytokines and ad 478 Toronto Hepatocellular Carci 348 Treatment not needed for hyp 407 Trends in the burden of cirr 128 Undetected asymptomatic alco 378 When to perform surgical res 365 Whole blood coagulation test 351 Long term outcome after rese 423 MicroRNA-26 expression is si 436 Endothelial nitric oxide syn 435 A New Clinically-Based Stagi 127 A Pilot Safety Study of Natu 440 A randomized controlled stud 402 Albi score predicts survival 490 Analytic Morphomics Predicts 418 Antiviral Therapy for Chroni 207 Blood alpha-fetoprotein leve 437 Building of a Scoring Model 419 Characteristics of etiology- 370 Clinicopathologic analysis o 465 Combination of modified Resp 468 Comparison of Hepatocellular 451 Comprehensive analyses of mu 406 Conversion therapy with hepa 399 Current knowledge of guideli 434 Development of a model predi 377 Dysregulated peripheral and 454 Effect of Antiviral Therapy 368 Efficacy and safety of mirip 383 Efficacy of Radiotherapy in 433 Elevated Serum Wisteria flor 408 Etiological difference in bo 461 Exploration of cancer-prone 430
Page 2 and 3:
208A AASLD ABSTRACTS HEPATOLOGY, Oc
Page 4 and 5:
Page 6 and 7:
Page 8 and 9:
Page 10 and 11:
Page 12 and 13:
Page 14 and 15:
Page 16 and 17:
Page 18 and 19:
Page 20 and 21:
Page 22 and 23:
Page 24 and 25:
Page 26 and 27:
Page 28 and 29:
Page 30 and 31:
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
Page 246 and 247:
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
Page 256 and 257:
Page 258 and 259:
Page 260 and 261:
Page 262 and 263:
Page 264 and 265:
Page 266 and 267:
Page 268 and 269:
Page 270 and 271:
Page 272 and 273:
Page 274 and 275:
Page 276 and 277:
Page 278 and 279:
Page 280 and 281:
Page 282 and 283:
Page 284 and 285:
Page 286 and 287:
Page 288 and 289:
Page 290 and 291:
Page 292 and 293:
Page 294 and 295:
Page 296 and 297:
Page 298 and 299:
Page 300 and 301:
Page 302 and 303:
Page 304 and 305:
Page 306 and 307:
Page 308 and 309:
Page 310 and 311:
Page 312 and 313:
Page 314 and 315:
Page 316 and 317:
Page 318 and 319:
Page 320 and 321:
Page 322 and 323:
Page 324 and 325:
Page 326 and 327:
Page 328 and 329:
Page 330 and 331:
Page 332 and 333:
Page 334 and 335:
Page 336 and 337:
Page 338 and 339:
Page 340 and 341:
Page 342 and 343:
Page 344 and 345:
Page 346 and 347:
Page 348 and 349:
Page 350 and 351:
Page 352 and 353:
Page 354 and 355:
Page 356 and 357:
Page 358 and 359:
Page 360 and 361:
Page 362 and 363:
Page 364 and 365:
Page 366 and 367:
Page 368 and 369:
Page 370 and 371:
Page 372 and 373:
Page 374 and 375:
Page 376 and 377:
Page 378 and 379:
Page 380 and 381:
Page 382 and 383:
Page 384 and 385:
Page 386 and 387:
Page 388 and 389:
Page 390 and 391:
Page 392 and 393:
Page 394 and 395:
Page 396 and 397:
Page 398 and 399:
Page 400 and 401:
Page 402 and 403:
Page 404 and 405:
Page 406 and 407:
Page 408 and 409:
Page 410 and 411:
Page 412 and 413:
Page 414 and 415:
Page 416 and 417:
Page 418 and 419:
Page 420 and 421:
Page 422 and 423:
Page 424 and 425:
Page 426 and 427:
Page 428 and 429:
Page 430 and 431:
Page 432 and 433:
Page 434 and 435:
Page 436 and 437:
Page 438 and 439:
Page 440 and 441:
Page 442 and 443:
Page 444 and 445:
Page 446 and 447:
Page 448 and 449:
Page 450 and 451:
Page 452 and 453:
Page 454 and 455:
Page 456 and 457:
Page 458 and 459:
Page 460 and 461:
Page 462 and 463:
Page 464 and 465:
Page 466 and 467:
Page 468 and 469:
Page 470 and 471:
Page 472 and 473:
Page 474 and 475:
Page 476 and 477:
Page 478 and 479:
Page 480 and 481:
Page 482 and 483:
Page 484 and 485:
Page 486 and 487:
Page 488 and 489:
Page 490 and 491:
Page 492 and 493:
Page 494 and 495:
Page 496 and 497:
Page 498 and 499:
Page 500 and 501:
Page 502 and 503:
Page 504 and 505:
Page 506 and 507:
Page 508 and 509:
Page 510 and 511:
Page 512 and 513:
Page 514 and 515:
Page 516 and 517:
Page 518 and 519:
Page 520 and 521:
Page 522 and 523:
Page 524 and 525:
Page 526 and 527:
Page 528 and 529:
Page 530 and 531:
Page 532 and 533:
Page 534 and 535:
Page 536 and 537:
Page 538 and 539:
Page 540 and 541:
Page 542 and 543:
Page 544 and 545:
Page 546 and 547:
Page 548 and 549:
Page 550 and 551:
Page 552 and 553:
Page 554 and 555:
Page 556 and 557:
Page 558 and 559:
Page 560 and 561:
Page 562 and 563:
Page 564 and 565:
Page 566 and 567:
Page 568 and 569:
Page 570 and 571:
Page 572 and 573:
Page 574 and 575:
Page 576 and 577:
Page 578 and 579:
Page 580 and 581:
Page 582 and 583:
Page 584 and 585:
Page 586 and 587:
Page 588 and 589:
Page 590 and 591:
Page 592 and 593:
Page 594 and 595:
Page 596 and 597:
Page 598 and 599:
Page 600 and 601:
Page 602 and 603:
Page 604 and 605:
Page 606 and 607:
Page 608 and 609:
Page 610 and 611:
Page 612 and 613:
Page 614 and 615:
Page 616 and 617:
Page 618 and 619:
Page 620 and 621:
Page 622 and 623:
Page 624 and 625:
Page 626 and 627:
Page 628 and 629:
Page 630 and 631:
Page 632 and 633:
Page 634 and 635:
Page 636 and 637:
Page 638 and 639:
Page 640 and 641:
Page 642 and 643:
Page 644 and 645:
Page 646 and 647:
Page 648 and 649:
Page 650 and 651:
Page 652 and 653:
Page 654 and 655:
Page 656 and 657:
Page 658 and 659:
Page 660 and 661:
Page 662 and 663:
Page 664 and 665:
Page 666 and 667:
Page 668 and 669:
Page 670 and 671:
Page 672 and 673:
Page 674 and 675:
Page 676 and 677:
Page 678 and 679:
Page 680 and 681:
Page 682 and 683:
Page 684 and 685:
Page 686 and 687:
Page 688 and 689:
Page 690 and 691:
Page 692 and 693:
Page 694 and 695:
Page 696 and 697:
Page 698 and 699:
Page 700 and 701:
Page 702 and 703:
Page 704 and 705:
Page 706 and 707:
Page 708 and 709:
Page 710 and 711:
Page 712 and 713:
Page 714 and 715:
Page 716 and 717:
Page 718 and 719:
Page 720 and 721:
Page 722 and 723:
Page 724 and 725:
Page 726 and 727:
Page 728 and 729:
Page 730 and 731:
Page 732 and 733:
Page 734 and 735:
Page 736 and 737:
Page 738 and 739:
Page 740 and 741:
Page 742 and 743:
Page 744 and 745:
Page 746 and 747:
Page 748 and 749:
Page 750 and 751:
Page 752 and 753:
Page 754 and 755:
Page 756 and 757:
Page 758 and 759:
Page 760 and 761:
Page 762 and 763:
Page 764 and 765:
Page 766 and 767:
Page 768 and 769:
Page 770 and 771:
Page 772 and 773:
Page 774 and 775:
Page 776 and 777:
Page 778 and 779:
Page 780 and 781:
Page 782 and 783:
Page 784 and 785:
Page 786 and 787:
Page 788 and 789:
Page 790 and 791:
Page 792 and 793:
Page 794 and 795:
1000A AASLD ABSTRACTS HEPATOLOGY, O
Page 796 and 797:
Page 798 and 799:
Page 800 and 801:
Page 802 and 803:
Page 804 and 805:
Page 806 and 807:
Page 808 and 809:
Page 810 and 811:
Page 812 and 813:
Page 814 and 815:
Page 816 and 817:
Page 818 and 819:
Page 820 and 821:
Page 822 and 823:
Page 824 and 825:
Page 826 and 827:
Page 828 and 829:
Page 830 and 831:
Page 832 and 833:
Page 834 and 835:
Page 836 and 837:
Page 838 and 839:
Page 840 and 841:
Page 842 and 843:
Page 844 and 845:
Page 846 and 847:
Page 848 and 849:
Page 850 and 851:
Page 852 and 853:
Page 854 and 855:
Page 856 and 857:
Page 858 and 859:
Page 860 and 861:
Page 862 and 863:
Page 864 and 865:
Page 866 and 867:
Page 868 and 869:
Page 870 and 871:
Page 872 and 873:
Page 874 and 875:
Page 876 and 877:
Page 878 and 879:
Page 880 and 881:
Page 882 and 883:
Page 884 and 885:
Page 886 and 887:
Page 888 and 889:
Page 890 and 891:
Page 892 and 893:
Page 894 and 895:
Page 896 and 897:
Page 898 and 899:
Page 900 and 901:
Page 902 and 903:
Page 904 and 905:
Page 906 and 907:
Page 908 and 909:
Page 910 and 911:
Page 912 and 913:
Page 914 and 915:
Page 916 and 917:
Page 918 and 919:
Page 920 and 921:
Page 922 and 923:
Page 924 and 925:
Page 926 and 927:
Page 928 and 929:
Page 930 and 931:
Page 932 and 933:
Page 934 and 935:
Page 936 and 937:
Page 938 and 939:
Page 940 and 941:
Page 942 and 943:
Page 944 and 945:
Page 946 and 947:
Page 948 and 949:
Page 950 and 951:
Page 952 and 953:
Page 954 and 955:
Page 956 and 957:
Page 958 and 959:
Page 960 and 961:
Page 962 and 963:
Page 964 and 965:
Page 966 and 967:
Page 968 and 969:
Page 970 and 971:
Page 972 and 973:
Page 974 and 975:
Page 976 and 977:
Page 978 and 979:
Page 980 and 981:
Page 982 and 983:
Page 984 and 985:
Page 986 and 987:
Page 988 and 989:
Page 990 and 991:
Page 992 and 993:
Page 994 and 995:
Page 996 and 997:
Page 998 and 999:
Page 1000 and 1001:
Page 1002 and 1003:
Page 1004 and 1005:
Page 1006 and 1007:
Page 1008 and 1009:
Page 1010 and 1011:
Page 1012 and 1013:
Page 1014 and 1015:
Page 1016 and 1017:
Page 1018 and 1019:
Page 1020 and 1021:
Page 1022 and 1023:
Page 1024 and 1025:
Page 1026 and 1027:
Page 1028 and 1029:
Page 1030 and 1031:
Page 1032 and 1033:
Page 1034 and 1035:
Page 1036 and 1037:
Page 1038 and 1039:
Page 1040 and 1041:
Page 1042 and 1043:
Page 1044 and 1045:
Page 1046 and 1047:
Page 1048 and 1049:
Page 1050 and 1051:
Page 1052 and 1053:
Page 1054 and 1055:
Page 1056 and 1057:
Page 1058 and 1059:
Page 1060 and 1061:
Page 1062 and 1063:
Page 1064 and 1065:
Page 1066 and 1067:
Page 1068 and 1069:
Page 1070 and 1071:
Page 1072 and 1073:
Page 1074 and 1075:
Page 1076 and 1077:
Page 1078 and 1079:
Page 1080 and 1081:
Page 1082 and 1083:
Page 1084 and 1085:
Page 1086 and 1087:
Page 1088 and 1089:
Page 1090 and 1091:
Page 1092 and 1093:
Page 1094 and 1095:
Page 1096 and 1097:
Page 1098 and 1099:
Page 1100 and 1101:
Page 1102 and 1103:
Page 1104 and 1105:
Page 1106 and 1107:
1312A AUTHOR INDEX HEPATOLOGY, Octo
Page 1108 and 1109:
Page 1110 and 1111:
Page 1112 and 1113:
Page 1114 and 1115: 1320A AUTHOR INDEX HEPATOLOGY, Octo
Page 1160 and 1161: 1366A CATEGORY INDEX HEPATOLOGY, Oc
Page 1172: 1378A CATEGORY INDEX HEPATOLOGY, Oc
show all

studies

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?